期刊文献+

罗格列酮对高糖环境下人脐静脉内皮细胞作用的研究 被引量:2

Effects of rosiglitazone on activation of human umbilical vein endothelial cells in high glucose environment
下载PDF
导出
摘要 目的研究罗格列酮对高糖环境下人脐静脉内皮细胞促血管生成功能的影响及其机制。方法通过MTT检测法、细胞划痕实验,探讨罗格列酮在高糖环境下对人脐静脉内皮细胞(HUVEC)的增殖与迁移能力的影响,并用ELISA方法检测经罗格列酮作用后高糖培养基上清中VEGF、SDF-1的含量,进行统计分析。结果经罗格列酮药物处理后的HUVEC增殖和迁移能力明显高于高糖组,且培养基中VEGF和SDF-1的含量也有显著升高。AKT阻断剂可以阻断罗格列酮对HUVEC增殖、迁移和分泌功能的促进作用。结论罗格列酮在高糖环境下可显著促进HUVEC的增殖、迁移和分泌功能,AKT信号通路在这一过程中发挥着重要的作用。 Objective To investigate the effects of rosiglitazone on proangiogenesis function of human umbilical vein endothelial cells ( HUVEC) in high glucose environment. Methods HUVECs were cultured in high glucose environment and stimulated by rosiglitazone. MTT, cell scratch test and Transwell assay were used to detect HUVEC proliferation and migration. The concentration of VEGF, SDF-1 was also detected in the supernatant. Results Rosiglitazone could effectively promote HUVEC proliferation and migration. The concentration of VEGF and SDF-1 in rosiglitazone stimulated supernatant was higher than that in high glucose group. The inhibition of AKT signal could block the promotion of rosiglitazone on the HUVEC proliferation, migration and secretion. Conclusion Rosiglitazone could significantly promote HUVEC secretion, proliferation and migration in high glucose environment. AKT signal played an important role in this process.
出处 《局解手术学杂志》 2015年第3期253-256,共4页 Journal of Regional Anatomy and Operative Surgery
基金 国家自然科学基金面上项目(31470046)
关键词 罗格列酮 人脐静脉内皮细胞 高糖环境 活化 rosiglitazone HUVEC high glucose environment activation
  • 相关文献

参考文献5

二级参考文献25

  • 1祝建中,赵基栋,苗宗宁,钱寒光.体外诱导骨髓间充质干细胞分化为血管内皮细胞的实验研究[J].中国微循环,2005,9(6):409-411. 被引量:10
  • 2黄斌,罗琳,韩文群,谢雪,罗先策,魏东.马来酸罗格列酮对2型糖尿病患者糖脂代谢、胰岛素抵抗及血清炎症因子的影响[J].中国糖尿病杂志,2006,14(1):9-10. 被引量:27
  • 3Ford ES. Body mass index, diabetes, and C - reactive protein among U. S. adults. Diabetes Care, 1999,22(12) : 1971 - 1977.
  • 4Pickup JC, Crook MA. Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia, 1998, 41 ( 10 ) : 1241 - 1248.
  • 5Pradhan AD, Manson JE, Nader Rifai N, et al. C reactive reactive protein, interleukin - 6, and risk of developing type 2 diabetes mellitus. JAMA, 2001,286 (3) : 327 - 334.
  • 6Taniguchi A, Nagasaka S, Fukushima M, et al. C - reactive protein and insulin resistance in non - obese Japanese type 2 diabetic patients. Metabolism, 2002,51(12) : 1578 - 1581.
  • 7Pradhan AD, Manson JE, Rifai N, et al. C - reactive protein, interleukin 6,and risk of developing type 2 diabetes mellitus. JAMA, 2001,286(3) :327 - 334.
  • 8Spiegelrnan BM. PPAR-gamma: adipogenic regulator and thiazolidinedrone receptor. Diabetes, 1998,47(4) :507 - 514.
  • 9Balfour JA, Plosker GL. Rosiglitazone. Drugs, 1999, 57 (6). 921.
  • 10Eposito K, Ciotola M, Carlo D, et al. Effecf of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care, 2006,29 ( 5 ) : 1071 - 1076.

共引文献198

同被引文献25

  • 1杨旭红,李鹏,戴文,熊小明,涂江华,吴树金,刘立英.罗格列酮对同型半胱氨酸硫内酯所致内皮细胞损伤的保护作用与PPARγ介导的抗氧化相关[J].中国动脉硬化杂志,2015,23(6):549-555. 被引量:3
  • 2张子平,张燕娥,苏文婷.临床路径在糖尿病患者健康教育中的应用[J].中国实用医刊,2010,37(14):94-95. 被引量:11
  • 3郑少雄.罗格列酮和心血管风险——近期文献解读[J].国际内分泌代谢杂志,2007,27(4):217-222. 被引量:2
  • 4万学红,声雪峰.诊断学[M].8版.北京:人民卫生出版社,2013.151-162.
  • 5Executive summary. Standards of medical care in diabetes--2013 [D]. Diabetes Care, 2013, 36 Suppl 1: $4-10.
  • 6Purrcllo F, Rabuazza AM. Metabolic factors that affect beta-cell function and survival [J]. Diabet Nu~" Mctab, 2000, 13: 84-91.
  • 7Garvey K, Wolfsdorf JI. The impact of technology on current diabe- tes management [J]. Pediatr Clin N Am, 2015, 62(4): 873-888.
  • 8Intensive blood-glucose control with sulphonylureas or insulin com- pared with conventional treatment and risk of complications in pa- tients with type 2 diabetes (UKPDS 33) [J]. Lancet, 1998, 352 (9131): 837-853.
  • 9Fogli S, Pellegrini S, Adinolfi B, et al. Rosiglitazone reverses salbutamol-induced (2)-adrenoceptor tolerance in airway smooth muscle[J]. Br J Pharmacol, 2011, 162 (2): 378 391. DOI: 10. 1111/j. 1476-5381. 2010. 01021. x.
  • 10Aubert RE, Herrera V, Chen W, et al. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes [J]. Diabetes Obes Metab, 2010, 12 (8) : 716- 721. DOI:10. illl/j. 1463-1326. 2010. 01225. x.

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部